William D. Shrader

BD Biosciences (United States) — United States

Medicine · Health Sciences

21h-index1.6kcitations38works9.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Blood Coagulation and Thrombosis Mechanisms(18), Coagulation, Bradykinin, Polyphosphates, and Angioedema(15), Protease and Inhibitor Mechanisms(6), Hemophilia Treatment and Research(6), Mitochondrial Function and Pathology(5)

Publications38 total

Lessons from the Tim Greenamyre model
Neurobiology of Disease·2025Open Access
LRRK2 regulates production of reactive oxygen species in cell and animal models of Parkinson’s disease
Science Translational Medicine·2024· 26 cited
15-Lipoxygenase-Mediated Lipid Peroxidation Regulates LRRK2 Kinase Activity
2024· 1 citedOpen Access
Targeting ferroptosis: A novel therapeutic strategy for the treatment of mitochondrial disease-related epilepsy
PLoS ONE·2019· 97 citedOpen Access
Vitamin E hydroquinone is an endogenous regulator of ferroptosis via redox control of 15-lipoxygenase
PLoS ONE·2018· 171 citedOpen Access
EPI-743 reverses the progression of the pediatric mitochondrial disease—Genetically defined Leigh Syndrome
Molecular Genetics and Metabolism·2012· 185 cited
A0001 in Friedreich ataxia: Biochemical characterization and effects in a clinical trial
Movement Disorders·2012· 89 cited
Towards a modern definition of vitamin E—evidence for a quinone hypothesis
Bioorganic & Medicinal Chemistry Letters·2011· 13 cited
Initial experience in the treatment of inherited mitochondrial disease with EPI-743
Molecular Genetics and Metabolism·2011· 196 citedOpen Access
α-Tocotrienol quinone modulates oxidative stress response and the biochemistry of aging
Bioorganic & Medicinal Chemistry Letters·2011· 93 cited
Small Molecule Inhibitors of Plasma Kallikrein.
ChemInform·2006· 1 cited
Potent 4-amino-5-azaindole factor VIIa inhibitors
Bioorganic & Medicinal Chemistry Letters·2006· 34 citedOpen Access
Efforts toward oral bioavailability in factor VIIa inhibitors
Bioorganic & Medicinal Chemistry Letters·2006· 9 citedOpen Access
Factor VIIa Inhibitors: Gaining Selectivity within the Trypsin Family.
ChemInform·2006· 1 cited
Novel 5-azaindole factor VIIa inhibitors
Bioorganic & Medicinal Chemistry Letters·2006· 27 citedOpen Access
Factor VIIa inhibitors: Improved pharmacokinetic parameters
Bioorganic & Medicinal Chemistry Letters·2006· 13 citedOpen Access
Discovery of novel heterocyclic factor VIIa inhibitors
Bioorganic & Medicinal Chemistry Letters·2006· 26 citedOpen Access
Factor VIIa inhibitors: A prodrug strategy to improve oral bioavailability
Bioorganic & Medicinal Chemistry Letters·2006· 27 citedOpen Access
Factor VIIa inhibitors: Chemical optimization, preclinical pharmacokinetics, pharmacodynamics, and efficacy in an arterial baboon thrombosis model
Bioorganic & Medicinal Chemistry Letters·2006· 30 citedOpen Access
Small molecule inhibitors of plasma kallikrein
Bioorganic & Medicinal Chemistry Letters·2006· 8 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Paul A. Sprengeler(19), Wendy B. Young(15), B.A. Katz(12), Aleksandr Kolesnikov(11), Roopa Rai(9), Kyle Elrod(9), Huiyong Hu(8), Guy Miller(6), Christine Yu(6), Ellen M. Leahy(6), Akiko Amagata(5), A. Scott Hinman(5), Jana Burgess‐Henry(5), James W. Janc(5), Ellen Sanford(5), Joyce Mordenti(5), Viktoria Kheifets(4), Erik Verner(4), Christine Luong(4), Kieron E. Wesson(4)